Clarient introduces sequencing assay for solid tumors

8 April 2013 (Last Updated April 8th, 2013 18:30)

Clarient Diagnostic Services, a GE Healthcare company, has launched a new sequencing assay for the diagnosis of solid tumors.

Clarient Diagnostic Services, a GE Healthcare company, has launched a new sequencing assay for the diagnosis of solid tumors.

The assay was developed by leveraging the genomic capabilities offered by research laboratory SeqWright, which was recently acquired by GE Healthcare.

"The platform allows researchers to perform prospective and retrospective analysis and to understand which patients will respond to particular therapies."

The platform, which targets the 26 most common oncogenes and tumor suppressor genes of lung, breast colon and melanoma cancers, allows researchers to perform prospective and retrospective analysis and to understand which patients will respond to particular therapies.

In addition, the assay helps in stratifying patient populations for ongoing clinical trials and early research efforts.

Clarient Diagnostic Services chief medical officer Dr Kenneth Bloom said many pharmaceutical companies are focusing on particular key drivers of cancer to develop targeted therapies.

"By providing an assay limited to the most relevant and actionable genes in drug development today, we hope to further our mission of bringing clarity to a complex disease and aiding the biopharmaceutical industry in their clinical research endeavors," Bloom said.

"Additionally, because genomic sequencing procedures are important technologies for GE Healthcare's medical diagnostics business, availability of this assay allows us to offer a substantially wider range of services to the biopharmaceutical, diagnostic and research industries and eventually to health care providers and patients."

GE Healthcare, through its Clarient business, also offers comprehensive clinical and research assays for leukemia and lymphomas.